The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia - A report from the German Registry covering the period from 1998 to 2004

Annals of Hematology

Volumn 88, Issue 12, 2009, Pages 1237-1247

  Bacher, Ulrike ^a   Klyuchnikov, Evgeny ^a,b   Zabelina, Tatjana ^a   Ottinger, Hellmut ^c   Beelen, Dietrich W ^c   Schrezenmeier, Hubert ^c,d   Ehninger, Gerhard ^e   Müller, Carlheinz ^c   Berger, Jürgen ^f   Suttorp, Meinolf ^g   Kolb, Hans Jochem ^h   Kröger, Nicolaus ^a   Zander, Axel R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF HAMBURG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

Author keywords

Allogeneic stem cell transplantation (SCT); Chronic myeloid leukemia (CML); Dose reduced conditioning (RIC); German Registry of Stem Cell Transplantation (DRST); Myeloablative conditioning

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ADULT; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GRADING; CANCER REGISTRY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 70350341896     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0737-3     Document Type: Article

References (34)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417. doi: 10.1056/NEJMoa062867
2. Mauro MJ, Deininger MW (2006) Chronic myeloid leukemia in 2006: A perspective. Haematologica 91:152
3. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D (2007) Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: Focus on increasing use of unrelated donors. Bone Marrow Transplant 39:71-87. doi: 10.1038/sj.bmt.1705555
4. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM (2007) Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 137:461-467. doi: 10.1111/j.1365-2141.2007.06582.x
5. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172-183. doi: 10.1038/nrc1567
6. Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarani M, Lokey L (2007) Diagnosis and management of chronic myeloid leukemia: A survey of American and European practice patterns. Cancer 109:1365-1375. doi: 10.1002/cncr.22523
7. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820. doi: 10.1182/blood-2006-02-005686
8. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213. doi: 10.1182/blood-2006-09-046888
9. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546. doi: 10.1182/blood-2007-03-080689
10. Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR (2006) Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: A retrospective multicentre study. Eur J Haematol 76:9-17. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2321.x
11. Kujawski L, Talpaz M (2007) Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma 48:2310-2322. doi: 10.1080/10428190701665988
12. Frame D (2006) Chronic myeloid leukemia: Standard treatment options. Am J Health Syst Pharm 63:S10-S14. doi: 10.2146/ajhp060525
13. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106:2969-2976. doi: 10.1182/blood-2004-09-3544
14. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, De LM, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF (2006) Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38:203-209. doi: 10.1038/ sj.bmt.1705425
15. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763
16. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400. doi: 10.1182/ blood.V97.11.3390
17. Ottinger HD, Albert E, Arnold R, Beelen DW, Blasczyk R, Bunjes D, Burdach S, Ebell W, Ehninger G, Einsele H, Enczmann J, Fauser A, Friedrich W, Finke J, Gobel U, Goldmann SF, Gramatzki M, Helbig W, Kanz L, Klingebiel T, Kolb HJ, Kuhnl P, Loliger C, Muller CR, Grosse-Wilde H (1997) German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells. Bone Marrow Transplant 20:101-105. doi: 10.1038/sj.bmt.1700851
18. Ottinger HD, Muller CR, Goldmann SF, Albert E, Arnold R, Beelen DW, Blasczyk R, Bunjes D, Casper J, Ebell W, Ehninger G, Eiermann T, Einsele H, Fauser A, Ferencik S, Finke J, Hertenstein B, Heyll A, Klingebiel T, Knipper A, Kremens B, Kolb HJ, Kolbe K, Lenartz E, Lindemann M, Muller CA, Mytilineos J, Niederwieser D, Runde V, Sayer H, Schaefer UW, Schmitz N, Schroder S, Schulze-Rath R, Schwerdtfeger R, Siegert W, Thiele B, Zander AR, Grosse-Wilde H (2001) Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Ann Hematol 80:706-714. doi: 10.1007/s00277-001-0384-9
19. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, De WT, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087-1092. doi: 10.1016/S0140-6736(98) 03030-X
20. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513-521
21. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG, Aschan J, Beelen DW, Basara N, Kumlien G, Fauser AA, Runde V (2001) No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98:1739-1745. doi: 10.1182/blood.V98.6.1739
22. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A, Runde V, Grosse-Wilde H, Beelen DW, Schaefer UW (2002) Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99:1130-1135
23. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR Jr, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringden O, Tomany SC, Rowlings PA, Van Hoef ME, Gratwohl A (2000) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95:3702-3709
24. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJ (2000) Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 95:2219-2225
25. Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P (2002) Allogeneic bone marrow transplantation for chronic myelogenous leukemia: Comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99:1971-1977. doi: 10.1182/blood.V99.6.1971
26. Faber E, Koza V, Vitek A, Mayer J, Sedlacek P, Zak P, Zapletalova J, Benesova K, Krejcova H, Steinerova K, Maresova I, Cetkovsky P (2007) Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning-a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma 54:443-446
27. Chen MH, Chiou TJ, Lin PC, Gau JP, Hsu HC, Hsiao LT, Liu JH, Chen PM (2007) Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. Int J Hematol 86:275-281. doi: 10.1007/BF03006933
28. Kojima R, Kami M, Kanda Y, Kusumi E, Kishi Y, Tanaka Y, Yoshioka S, Morishima S, Fujisawa S, Mori SI, Kasai M, Hatanaka K, Tajima K, Kasai M, Mitani K, Ichinohe T, Hirai H, Taniguchi S, Sakamaki H, Harada M, Takaue Y (2005) Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 36:667-674. doi: 10.1038/sj.bmt.1705122
29. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De LM, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M (2002) Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100:1590-1595
30. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, Gadner H, Sufliarska S, Stary J, Gschaidmeier H, Guilhot F, Suttorp M (2006) Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 20:187-192. doi: 10.1038/sj.leu.2404051
31. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, Craddock CF (2007) Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 110:4614-4617. doi: 10.1182/blood-2007-04-082990
32. DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ (2004) Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 10:5065-5071. doi: 10.1158/1078-0432.CCR-03-0580
33. Atallah E, Kantarjian H, De Lima M, Borthakur G, Wierda W, Champlin R, Cortes J (2006) The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). Blood 108. abstract 4520.
34. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M (2006) Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108:1421-1423. doi: 10.1182/blood-2006-02-001933